HSP90AA1 and neoplasm: HEMTAC 26 dose-dependently decreased the levels of CDK4/6 and inhibited tumor growth in the B16F10 Xenograft Model.537 Undoubtedly, the discovery of multi-specific molecules based on HSP90 expands the scope of TPD strategies and may avoid drug resistance mediated by mutations of specific ubiquitin E3 ligases.